Aldeyra The - Asset Resilience Ratio
Aldeyra The (ALDX) has an Asset Resilience Ratio of 20.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Aldeyra The's Asset Resilience Ratio has changed over time. Check Aldeyra The (ALDX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Aldeyra The's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Aldeyra The stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.96 Million | 20.51% |
| Total Liquid Assets | $15.96 Million | 20.51% |
Asset Resilience Insights
- Good Liquidity Position: Aldeyra The maintains a healthy 20.51% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aldeyra The Industry Peers by Asset Resilience Ratio
Compare Aldeyra The's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Aldeyra The (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Aldeyra The.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 44.57% | $46.62 Million | $104.61 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $148.33 Million | -- |
| 2022-12-31 | 16.48% | $29.88 Million | $181.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $233.14 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $83.35 Million | -- |
| 2019-12-31 | 38.32% | $28.94 Million | $75.52 Million | -10.31pp |
| 2018-12-31 | 48.63% | $46.24 Million | $95.09 Million | -3.26pp |
| 2017-12-31 | 51.89% | $22.92 Million | $44.17 Million | +0.69pp |
| 2016-12-31 | 51.21% | $12.90 Million | $25.19 Million | +5.32pp |
| 2015-12-31 | 45.89% | $12.94 Million | $28.20 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $8.79 Million | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more